Funds will be used to establish clinical proof of concept for Artiva’s CAR-NK and universal NK cell therapies Artiva has exclusive access to a proprietary large-scale NK cell manufacturing platform and infrastructure First clinical study planned for later this year followed by two additional clinical programs SAN DIEGO, June 26, 2020 – Artiva Biotherapeutics, Inc.,…
